PARP inhibitors are an FDA-approved treatment for breast, ovarian and prostate cancers. This project
aims to develop 3 new classes of PARP inhibitors, 2 of which can target multiple pathways with a single
drug, helping to prevent resistance to the PARP inhibitors and enabling the combination of 2 drug
treatments without the added side effects that a sequential treatment would have. The other class of
PARP inhibitor can cross the blood-brain barrier, providing another treatment option for brain tumours.
Successful development of the 3 inhibitors will result in increased research and development
expenditures, and increased yearly revenue for Rakovina Therapeutics.